SlideShare a Scribd company logo
Adrenaline & noradrenaline
Dr Nida Fatima
jawaharlal nehru medical college ,
AMU ALIGARH
adrenaline
ā€¢ Catecholamine,
sympatho-mimetic
monoamine, derived -
phenylalanine and
tyrosine.
ā€¢ C9H13NO3
ā€¢ MOL WT:183.20442
g/mol
Biosynthesis
HO
NH2
CO2H
L-Tyrosine
Tyrosine
hydroxylase HO
NH2
CO2H
Levodopa
HO
HO
NH2
Dopamine
HO
Dopa
Decarboxylase
Dopamine
ļ¢-hydroxylase
HO
HO
NH2
OH
Norepinephrine
(Noradrenaline)
HO
HO
NHMe
OH
Epinephrine
(Adrenaline)
N-methyl transferase
(in Adrenal medulla)
Mechanism of action
Types of ļ”-adrenergic
receptor
Receptor Sites of action Effects
ļ”1 smooth muscle,
heart, and liver
vasoconstriction,
intestinal relaxation,
uterine contraction and
pupillary dilation,
ļ”2 platelets, vascular smooth
muscle, nerve termini,
and pancreatic islets
platelet aggregation,
vasoconstriction, and
inhibition of NE release
and of insulin secretion.
Types of Ī²-adrenergic
receptor
Receptor Sites of action Effects
Ī²1
Heart tachycardia
Ī²2 lungs,
gastrointestinal
tract, liver, uterus,
vascular smooth
and skeletal muscle
Bronchodilatation
Smooth muscle
relaxation, sphincter
constriction
Ī²3 Fat cells
Receptors and signal
transduction in the ANS
Adrenergic Receptors
ļ”1A
ļ”1 ļ¢
ļ”2
ļ”1B ļ”1D ļ”2A ļ”2B ļ”2C ļ¢1 ļ¢2 ļ¢3
Classification of Adrenergic Hormone
Receptors
Receptor Agonists
Second
Messenger
G protein
alpha1 (ļ”1) NE > E IP3/Ca2+; DAG Gq
alpha2 (ļ”2) E > NE ļ‚Æ cyclic AMP Gi
beta1 (ļ¢1) E = NE ļ‚­ cyclic AMP Gs
beta2 (ļ¢2) E >> NE ļ‚­ cyclic AMP Gs
E = epinephrine; NE = norepinephrine
Cardiovascular effects of
adrenergic agonists
PHARMACODYNAMICS
ADRENALINE PREPARATIONS
ā€¢ Clear solution conc. of 1:1000 (1ml amp) or
1:10 000 (10 ml mini-jet for resuscitation).
ā€¢ Along with L.A- conc. of 1:200 000, upto
1:80 000 (Lignocaine 2% for dental inj).
ā€¢ Auto-injectors for use in anaphylaxis
ā€¢ 0.3 mg and 0.15 mg (EpiPenĀ®) for i.m inj.
SIDE EFFECTS
ā€¢ Exaggerated effects of adrenaline, overdosage,
inadvertent i.v injection , inappropriate use.
ā€¢ palpitations, tremor, light headedness
ā€¢ tachycardia, arrhythmias, hypertension
ā€¢ cerebral haemorrhage ,acute pulmonary edema
ā€¢ lactic acidosis
Effects of adrenaline on organs and
tissues in the body
ORGAN EFFECT RECEPTOR TYPE
Heart Increase heart rate
Increased contractility
Ī²1
Ī²1
Blood vessels Vasoconstriction
Vasodilation
Ī±1
Ī²2
Lungs Bronchodilation Ī²2
Uterus Relaxation Ī²2
ORGAN EFFECT RECEPTOR
Metabolism Inhibits pancreatic insulin secretion Ī±2Ī²2
Glycogenolysis in liver and muscle Ī±1Ī²2
Glycolysis in muscle Ī±1Ī²2
Gluconeogenesis Ī±1Ī²2
Glucagon secretion in pancreas Ī±2
ACTH secretion by pituitary Ī²
Lipolysis in adipose tissue Ī²2Ī²3
Renin secretion from kidney Ī²1Ī²2
RESUSCITATION
ā€¢ Adrenaline - DOC -cardiac arrest.
ā€¢ Main action - ā†‘ vascular resistance via Ī±1
vasoconstriction ā†’ improves perfusion
pressure to the myocardium and brain.
ā€¢ Adrenaline -greatest effect when given i.v
intraosseous route if i.v route not patent.
ADR IN ACLS
ā€¢ VF/VT cardiac arrest -1mg ,in the third cycle
after 2 shocks and then every 3-5 minutes
(alternate CPR cycles).
ā€¢ PEA arrest -1 mg, and then every 3-5
minutes (alternate cycles).
ā€¢ Children-10 micrograms ( 0.1 mL of the
1:10,000 solution) per kg i.v ,repeated every
3-5 minutes.
ADR IN ACLS
ā€¢ Bradycardia: 1mg ADR with 500ml of NS or
D5W. Infusion @ 2-10 Āµg/min (titrated to
effect).
ā€¢ ROSC hypotension: 0.1-0.5 mcg/kg/min
ā€¢ Endotracheal Tube: 2-2.5mg ADR is diluted
in 10cc NS and given directly into ET tube.
ANAPHYLAXIS
ā€¢ Adrenaline is the drug of choice.
ā€¢ Ī±1-agonist, reverses -peripheral vasodilation
by inflammatory mediator release,ā†“ oedema.
ā€¢ Ī² activity dilates bronchial airways,
ā†‘myocardial contractility, ā†“ histamine and
LT release and ā†“ severity of IgE-mediated
allergic reactions.
Management of acute anaphylaxis
AGE IM DOSE (micrograms)
(ml of 1:1000 solution)
IV DOSE (micrograms)
(ml of 1:10 000 solution)
Adult 500 micrograms (0.5 ml) 50 micrograms (0.5 ml)
titrated to effect
Child > 12
years
500 micrograms (0.5 ml) 50 micrograms (0.5 ml)
titrated to effect
Child 6-12
years
300 micrograms (0.3 ml) 1 microgram/kg titrated
to effect
Child < 6 years 150 micrograms (0.15 ml) 1 microgram/kg titrated
to effect
ANAPHYLAXIS DOSES
ā€¢ Adults-initial dose is 100 to 500 microgram
(0.1 to 0.5 mL of the 1:1,000 sol) SC or IM.
ā€¢ repeated at 20 minute to 4 hour intervals
ā€¢ severe anaphylactic shock, slow and
cautious IV administration-100 to 250
microgram
ā€¢ Children-10 microgram per kg SC repeated
at intervals of 20 min to 4 hrs
INOTROPIC SUPPORT
ā€¢ Continuous infusion in ICU- via CVP line,
with invasive blood pressure monitoring.
ā€¢ Indications :
ā€¢ profoundly low blood pressure,
ā€¢ shock,
ā€¢ low cardiac output states and
ā€¢ status asthmaticus.
ā€¢ There is no single appropriate
concentration.
ā€¢ 4 mg Adrenaline diluted to 50 ml in saline or
5% dextrose, infused by means of a syringe
driver.
ā€¢ Rate of infusion -titrated to effect, to achieve
target blood pressure.
AIRWAY OBSTRUCTION
ā€¢ Severe croup-m/c airway indication for Adr.
ā€¢ angio-oedema- life threatening obstruction.
ā€¢ racemic adrenaline -nebulized route.
ā€¢ MOA-reduce the local inflammatory process
and to provide local vasoconstriction-
reducing obstruction caused by oedema.
DOSAGE
ā€¢ L-Adrenaline-0.5 ml/kg of a 1:1000 solution
(maximum of 5 ml) placed undiluted into
the chamber of the nebulizer for children.
ā€¢ Racemic -0.05 ml/kg (max 1.5 ml) of 2.25%
sol diluted to 4 ml NS.
Topical or local vasoconstriction
ā€¢ Local vasoconstricting action- adrenaline
used as a topical application or combined
with local anaesthetic to be infiltrated.
ā€¢ Prolongs its action, reduces bleeding at the
site of injection or topically (nasal mucosa
as part of Moffatā€™s solution)
CONTRA-INDICATIONS
ā€¢ Known hypersensitivity
ā€¢ Shock (other than anaphylactic shock)
ā€¢ Cardiac dilatation and insufficiency
ā€¢ Hypertension
ā€¢ Ischaemic heart disease
ā€¢ Arrhythmias
ā€¢ Cerebral arteriosclerosis
ā€¢ Diabetes mellitusĀ·
ā€¢ Hyperthyroidism
ā€¢ Narrow angle (congestive) glaucoma
ā€¢ Organic brain damage
ā€¢ Phaeochromocytoma / thyrotoxicosis
ā€¢ halogenated hydrocarbons or cyclopropane
ā€¢ L.A in fingers, toes, ears, nose or genitalia
ā€¢ Labour
NORADRENALINE
Mol formula C8H11NO3
Catecholamine with multiple
roles:
ā€¢Hormone
ā€¢Neurotransmitter.
BIOSYNTHESIS
ACTIONS
ā€¢ Stress hormone
ā€¢ Fight-or-flight response
ā€¢ Increases heart rate
ā€¢ Triggers the release of glucose
ā€¢ Increases blood flow to skeletal muscle.
ā€¢ Suppress neuro-inflammation.
Noradrenergic system
ā€¢ Amygdala
ā€¢ Cingulate gyrus
ā€¢ Cingulum
ā€¢ Hippocampus
ā€¢ Hypothalamus
ā€¢Neocortex
ā€¢ Spinal cord
ā€¢ Striatum
ā€¢ Thalamus
VESICULAR TRANSPORT
ā€¢ Between the decarboxylation and final Ī²-
oxidation, norepinephrine is transported
into synaptic vesicles.
ā€¢ Accomplished by vesicular monoamine
transporter (VMAT) in the lipid bilayer.
ā€¢ This transporter has equal affinity for
norepinephrine, epinephrine and
isoprenaline
PHARMACODYNAMICS
ā€¢ Potent action-both a1 & b1 receptors
ā€“Little action on b2
ā€“Causes potent vasoconstriction (Ī±)
ā€“Lacks bronchodilating effect
ā€“ā†‘ systolic, diastolic & MAP
ā€“Reflex bradycardia
ā€“Metabolic acidosis
PHARMACOKINETICS
Onset- 1-2 min
Duration- 1-2 min
Metabolism- by COMT and MAO
Distribution
ā€¢ Sympathetic nervous tissue.
ā€¢ Crosses the placenta not blood-brain barrier.
Excretion- mainly urine (84-96%)
HYPOTENSIVE STATES
ā€¢ First-line therapy for maintenance of B.P
and tissue perfusion in septic shock.
ā€¢ adjunct to correct hemodynamic imbalances
ā€¢ Start:8-12 Āµg/min IV infusion; titrate to
effect
ā€¢ Maintenance: 2-4 mcg/min IV infusion
ā€¢ Septic shock: 0.01-3 mcg/kg/min IV infusion
Cardiac Arrest
ā€¢ Adjunctive Treatment in Cardiac Arrest
ā€¢ Infusions of noradrenaline given during
cardiac arrest to restore and maintain an
adequate blood pressure after an effective
heartbeat and ventilation have been
established by other means.
ā€¢ Initial: 8-12 mcg/min IV infusion; titrate to
effect
ā€¢ Maintenance: 2-4 mcg/min IV infusion
DOSAGE
ā€¢ The usual dose range is 0.01-0.1 m/kg/min
ā€¢ Avg. adult maintenance dosage: 2ā€“4 Āµg/min
ā€¢ May require 8ā€“30 mcg/minute in cases of
refractory shock
ā€¢ Drug is diluted with 5% dextrose or
dextrose normal saline
ā€¢ administered through central venous line to
minimize the risk of extravasation and
subsequent tissue necrosis
ā€¢ control rate and strict monitoring
ā€¢ must not be stopped suddenly, gradually
withdrawn to avoid disastrous falls in blood
pressure
Noradrenaline infusion
Noradrenaline infusion
ā€¢ 4mg = 4mL of 1:1000
ā€¢ Add 4mL of 1:1000 Noradrenaline to 46mL
5% Glucose to make 50mL
ā€¢ Starting dose- 0.025microgram/kg/minute
ā€¢ the rate in mL/hour
INFUSION TABLE
ADVERSE EFFECTS
ļ‚§ Hypertension , bradycardia, arrhythmias,
palpitations
ļ‚§ Ischemic injury -potent vasoconstriction.
ļ‚§ Anxiety, insomnia, confusion,
ļ‚§ Headaches, psychosis
ļ‚§ Weakness, tremor
ļ‚§ Anorexia, nausea and vomiting.
Extravasation
ā€¢ Infusion site-checked frequently for free flow.
ā€¢ Avoid extravasation of noradrenaline
ā€¢ Local necrosis -vasoconstrictive action
ā€¢ Blanching- change infusion site
ā€¢ Extravasation-infiltrate area ā†’ 10 ml-15 ml
of saline solution containing 5 mg to 10 mg of
phentolamine.
Comparison
Features Adrenaline Noradrenaline
Heart rate ā†‘ ā†“
Cardiac output ā†‘ā†‘ --
Blood pressure-systolic ā†‘ā†‘ ā†‘ā†‘
diastolic ā†‘ā†“ ā†‘ā†‘
mean ā†‘ ā†‘ā†‘
Bronchial muscle ā†“ā†“ --
Intestinal muscle ā†“ā†“ ā†“
Blood sugar ā†‘ā†‘ --, ā†‘
Drug interaction
ā€¢ Non-selective MAO inhibitors
ā€¢ selective MAO inhibitors
ā€¢ Linezolid
ā€¢ Thyroid hormones
ā€¢ Cardiac glycosides
ā€¢ Ergot alkaloids or oxytocin
# enhance the vasopressor and vasoconstrictive
effects.
CONTRA-INDICATIONS
ā€¢ Known hypersensitivity
ā€¢ hypotensive from blood volume deficits
ā€¢ mesenteric or peripheral vascular thrombosis
ā€¢ Cyclopropane and halothane anesthetics
adrenalinenoradrenaline-150926040208-lva1-app6892.pdf

More Related Content

Similar to adrenalinenoradrenaline-150926040208-lva1-app6892.pdf

cardiovascular_agents_(1).pptx
cardiovascular_agents_(1).pptxcardiovascular_agents_(1).pptx
cardiovascular_agents_(1).pptx
marina lotfy shawky
Ā 
Vasopressors in icu
Vasopressors in icuVasopressors in icu
Vasopressors in icu
AbhinovKandur
Ā 
alpha blocker, receptors, antagonist, mechanism of action
alpha blocker, receptors, antagonist,  mechanism of actionalpha blocker, receptors, antagonist,  mechanism of action
alpha blocker, receptors, antagonist, mechanism of action
NishiThawait
Ā 
SCORPION STING .pptx
SCORPION STING .pptxSCORPION STING .pptx
SCORPION STING .pptx
DR Venkata Ramana
Ā 
Acls pharmacology
Acls pharmacologyAcls pharmacology
Acls pharmacology
ZahidulHasan11
Ā 
shreyadas303.pptx
shreyadas303.pptxshreyadas303.pptx
shreyadas303.pptx
PranaviShewale
Ā 
Neurologic and Neurosurgical Emergencies for nursing students.pptx
Neurologic and Neurosurgical Emergencies for nursing students.pptxNeurologic and Neurosurgical Emergencies for nursing students.pptx
Neurologic and Neurosurgical Emergencies for nursing students.pptx
Dr Ganeshgouda Majigoudra Consultant Neurologist Nanjappa hospitals
Ā 
DRUG USE IN LABOUR.pptx
DRUG USE IN LABOUR.pptxDRUG USE IN LABOUR.pptx
DRUG USE IN LABOUR.pptx
bnssecond
Ā 
Seminar drug used in paediatric cardiology
Seminar drug used in paediatric cardiologySeminar drug used in paediatric cardiology
Seminar drug used in paediatric cardiology
Kashid Omar
Ā 
nknn.pptx
nknn.pptxnknn.pptx
nknn.pptx
NajwaMustapa1
Ā 
Primary Adrenal Insufficiency
Primary Adrenal InsufficiencyPrimary Adrenal Insufficiency
Primary Adrenal Insufficiency
Amer Alboush
Ā 
anaesthesia-for-endocrine-disease.pdf
anaesthesia-for-endocrine-disease.pdfanaesthesia-for-endocrine-disease.pdf
anaesthesia-for-endocrine-disease.pdf
YcelYce1
Ā 
Emergency Drugs in OT and ICU.pptx
Emergency Drugs in OT and ICU.pptxEmergency Drugs in OT and ICU.pptx
Emergency Drugs in OT and ICU.pptx
MCOMS
Ā 
Adrenal_insufficiency_.pptx
Adrenal_insufficiency_.pptxAdrenal_insufficiency_.pptx
Adrenal_insufficiency_.pptx
Md Afgan Sk
Ā 
Drugs used in cath lab
Drugs used in cath labDrugs used in cath lab
Drugs used in cath lab
Farrukh Masood
Ā 
MALIGNANT HYPERTHERMIA
MALIGNANT HYPERTHERMIAMALIGNANT HYPERTHERMIA
MALIGNANT HYPERTHERMIA
Dr.Arun Marshalin
Ā 
Treatment of acute kidney injury "failure".
Treatment of acute kidney injury "failure".Treatment of acute kidney injury "failure".
Treatment of acute kidney injury "failure".
Amr Flifle
Ā 
inotropes
inotropesinotropes
inotropes
Abhay
Ā 
Inotropes
InotropesInotropes
Inotropes
Johny Wilbert
Ā 

Similar to adrenalinenoradrenaline-150926040208-lva1-app6892.pdf (20)

cardiovascular_agents_(1).pptx
cardiovascular_agents_(1).pptxcardiovascular_agents_(1).pptx
cardiovascular_agents_(1).pptx
Ā 
Vasopressors in icu
Vasopressors in icuVasopressors in icu
Vasopressors in icu
Ā 
alpha blocker, receptors, antagonist, mechanism of action
alpha blocker, receptors, antagonist,  mechanism of actionalpha blocker, receptors, antagonist,  mechanism of action
alpha blocker, receptors, antagonist, mechanism of action
Ā 
SCORPION STING .pptx
SCORPION STING .pptxSCORPION STING .pptx
SCORPION STING .pptx
Ā 
Acls pharmacology
Acls pharmacologyAcls pharmacology
Acls pharmacology
Ā 
Inotropes
InotropesInotropes
Inotropes
Ā 
shreyadas303.pptx
shreyadas303.pptxshreyadas303.pptx
shreyadas303.pptx
Ā 
Neurologic and Neurosurgical Emergencies for nursing students.pptx
Neurologic and Neurosurgical Emergencies for nursing students.pptxNeurologic and Neurosurgical Emergencies for nursing students.pptx
Neurologic and Neurosurgical Emergencies for nursing students.pptx
Ā 
DRUG USE IN LABOUR.pptx
DRUG USE IN LABOUR.pptxDRUG USE IN LABOUR.pptx
DRUG USE IN LABOUR.pptx
Ā 
Seminar drug used in paediatric cardiology
Seminar drug used in paediatric cardiologySeminar drug used in paediatric cardiology
Seminar drug used in paediatric cardiology
Ā 
nknn.pptx
nknn.pptxnknn.pptx
nknn.pptx
Ā 
Primary Adrenal Insufficiency
Primary Adrenal InsufficiencyPrimary Adrenal Insufficiency
Primary Adrenal Insufficiency
Ā 
anaesthesia-for-endocrine-disease.pdf
anaesthesia-for-endocrine-disease.pdfanaesthesia-for-endocrine-disease.pdf
anaesthesia-for-endocrine-disease.pdf
Ā 
Emergency Drugs in OT and ICU.pptx
Emergency Drugs in OT and ICU.pptxEmergency Drugs in OT and ICU.pptx
Emergency Drugs in OT and ICU.pptx
Ā 
Adrenal_insufficiency_.pptx
Adrenal_insufficiency_.pptxAdrenal_insufficiency_.pptx
Adrenal_insufficiency_.pptx
Ā 
Drugs used in cath lab
Drugs used in cath labDrugs used in cath lab
Drugs used in cath lab
Ā 
MALIGNANT HYPERTHERMIA
MALIGNANT HYPERTHERMIAMALIGNANT HYPERTHERMIA
MALIGNANT HYPERTHERMIA
Ā 
Treatment of acute kidney injury "failure".
Treatment of acute kidney injury "failure".Treatment of acute kidney injury "failure".
Treatment of acute kidney injury "failure".
Ā 
inotropes
inotropesinotropes
inotropes
Ā 
Inotropes
InotropesInotropes
Inotropes
Ā 

More from ChintuCH1

rheologydone-160221102012.pdf
rheologydone-160221102012.pdfrheologydone-160221102012.pdf
rheologydone-160221102012.pdf
ChintuCH1
Ā 
antidepressants-210723100900.pdf
antidepressants-210723100900.pdfantidepressants-210723100900.pdf
antidepressants-210723100900.pdf
ChintuCH1
Ā 
morphine-171119024007.pdf
morphine-171119024007.pdfmorphine-171119024007.pdf
morphine-171119024007.pdf
ChintuCH1
Ā 
morphinefentanylnida-151117150328-lva1-app6891.pdf
morphinefentanylnida-151117150328-lva1-app6891.pdfmorphinefentanylnida-151117150328-lva1-app6891.pdf
morphinefentanylnida-151117150328-lva1-app6891.pdf
ChintuCH1
Ā 
opioidanalgesics-111029153320-phpapp01.pdf
opioidanalgesics-111029153320-phpapp01.pdfopioidanalgesics-111029153320-phpapp01.pdf
opioidanalgesics-111029153320-phpapp01.pdf
ChintuCH1
Ā 
carbamazepinepublic-121124195050-phpapp01.pdf
carbamazepinepublic-121124195050-phpapp01.pdfcarbamazepinepublic-121124195050-phpapp01.pdf
carbamazepinepublic-121124195050-phpapp01.pdf
ChintuCH1
Ā 
preanaestheticmedicationgeneralanaesthetics-140927081752-phpapp01.pdf
preanaestheticmedicationgeneralanaesthetics-140927081752-phpapp01.pdfpreanaestheticmedicationgeneralanaesthetics-140927081752-phpapp01.pdf
preanaestheticmedicationgeneralanaesthetics-140927081752-phpapp01.pdf
ChintuCH1
Ā 
adrenalin-180418180059.pdf
adrenalin-180418180059.pdfadrenalin-180418180059.pdf
adrenalin-180418180059.pdf
ChintuCH1
Ā 
sympathomimetics-180115093558.pdf
sympathomimetics-180115093558.pdfsympathomimetics-180115093558.pdf
sympathomimetics-180115093558.pdf
ChintuCH1
Ā 
adrenalinefinalised-200703102926.pdf
adrenalinefinalised-200703102926.pdfadrenalinefinalised-200703102926.pdf
adrenalinefinalised-200703102926.pdf
ChintuCH1
Ā 
pyrrole-200404172118 (1).pdf
pyrrole-200404172118 (1).pdfpyrrole-200404172118 (1).pdf
pyrrole-200404172118 (1).pdf
ChintuCH1
Ā 
Colloidal dispersion
Colloidal dispersion Colloidal dispersion
Colloidal dispersion
ChintuCH1
Ā 

More from ChintuCH1 (12)

rheologydone-160221102012.pdf
rheologydone-160221102012.pdfrheologydone-160221102012.pdf
rheologydone-160221102012.pdf
Ā 
antidepressants-210723100900.pdf
antidepressants-210723100900.pdfantidepressants-210723100900.pdf
antidepressants-210723100900.pdf
Ā 
morphine-171119024007.pdf
morphine-171119024007.pdfmorphine-171119024007.pdf
morphine-171119024007.pdf
Ā 
morphinefentanylnida-151117150328-lva1-app6891.pdf
morphinefentanylnida-151117150328-lva1-app6891.pdfmorphinefentanylnida-151117150328-lva1-app6891.pdf
morphinefentanylnida-151117150328-lva1-app6891.pdf
Ā 
opioidanalgesics-111029153320-phpapp01.pdf
opioidanalgesics-111029153320-phpapp01.pdfopioidanalgesics-111029153320-phpapp01.pdf
opioidanalgesics-111029153320-phpapp01.pdf
Ā 
carbamazepinepublic-121124195050-phpapp01.pdf
carbamazepinepublic-121124195050-phpapp01.pdfcarbamazepinepublic-121124195050-phpapp01.pdf
carbamazepinepublic-121124195050-phpapp01.pdf
Ā 
preanaestheticmedicationgeneralanaesthetics-140927081752-phpapp01.pdf
preanaestheticmedicationgeneralanaesthetics-140927081752-phpapp01.pdfpreanaestheticmedicationgeneralanaesthetics-140927081752-phpapp01.pdf
preanaestheticmedicationgeneralanaesthetics-140927081752-phpapp01.pdf
Ā 
adrenalin-180418180059.pdf
adrenalin-180418180059.pdfadrenalin-180418180059.pdf
adrenalin-180418180059.pdf
Ā 
sympathomimetics-180115093558.pdf
sympathomimetics-180115093558.pdfsympathomimetics-180115093558.pdf
sympathomimetics-180115093558.pdf
Ā 
adrenalinefinalised-200703102926.pdf
adrenalinefinalised-200703102926.pdfadrenalinefinalised-200703102926.pdf
adrenalinefinalised-200703102926.pdf
Ā 
pyrrole-200404172118 (1).pdf
pyrrole-200404172118 (1).pdfpyrrole-200404172118 (1).pdf
pyrrole-200404172118 (1).pdf
Ā 
Colloidal dispersion
Colloidal dispersion Colloidal dispersion
Colloidal dispersion
Ā 

Recently uploaded

Unit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdfUnit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdf
Thiyagu K
Ā 
The approach at University of Liverpool.pptx
The approach at University of Liverpool.pptxThe approach at University of Liverpool.pptx
The approach at University of Liverpool.pptx
Jisc
Ā 
The Roman Empire A Historical Colossus.pdf
The Roman Empire A Historical Colossus.pdfThe Roman Empire A Historical Colossus.pdf
The Roman Empire A Historical Colossus.pdf
kaushalkr1407
Ā 
Overview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with MechanismOverview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with Mechanism
DeeptiGupta154
Ā 
How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...
Jisc
Ā 
A Strategic Approach: GenAI in Education
A Strategic Approach: GenAI in EducationA Strategic Approach: GenAI in Education
A Strategic Approach: GenAI in Education
Peter Windle
Ā 
Instructions for Submissions thorugh G- Classroom.pptx
Instructions for Submissions thorugh G- Classroom.pptxInstructions for Submissions thorugh G- Classroom.pptx
Instructions for Submissions thorugh G- Classroom.pptx
Jheel Barad
Ā 
Honest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptxHonest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptx
timhan337
Ā 
Lapbook sobre os Regimes TotalitƔrios.pdf
Lapbook sobre os Regimes TotalitƔrios.pdfLapbook sobre os Regimes TotalitƔrios.pdf
Lapbook sobre os Regimes TotalitƔrios.pdf
Jean Carlos Nunes PaixĆ£o
Ā 
The Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official PublicationThe Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official Publication
Delapenabediema
Ā 
Adversarial Attention Modeling for Multi-dimensional Emotion Regression.pdf
Adversarial Attention Modeling for Multi-dimensional Emotion Regression.pdfAdversarial Attention Modeling for Multi-dimensional Emotion Regression.pdf
Adversarial Attention Modeling for Multi-dimensional Emotion Regression.pdf
Po-Chuan Chen
Ā 
BƀI Tįŗ¬P Bį»” TRį»¢ TIįŗ¾NG ANH GLOBAL SUCCESS Lį»šP 3 - Cįŗ¢ NĂM (CƓ FILE NGHE Vƀ ĐƁP Ɓ...
BƀI Tįŗ¬P Bį»” TRį»¢ TIįŗ¾NG ANH GLOBAL SUCCESS Lį»šP 3 - Cįŗ¢ NĂM (CƓ FILE NGHE Vƀ ĐƁP Ɓ...BƀI Tįŗ¬P Bį»” TRį»¢ TIįŗ¾NG ANH GLOBAL SUCCESS Lį»šP 3 - Cįŗ¢ NĂM (CƓ FILE NGHE Vƀ ĐƁP Ɓ...
BƀI Tįŗ¬P Bį»” TRį»¢ TIįŗ¾NG ANH GLOBAL SUCCESS Lį»šP 3 - Cįŗ¢ NĂM (CƓ FILE NGHE Vƀ ĐƁP Ɓ...
Nguyen Thanh Tu Collection
Ā 
CACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdfCACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdf
camakaiclarkmusic
Ā 
Supporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptxSupporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptx
Jisc
Ā 
2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...
Sandy Millin
Ā 
Chapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptxChapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptx
Mohd Adib Abd Muin, Senior Lecturer at Universiti Utara Malaysia
Ā 
Palestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptxPalestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptx
RaedMohamed3
Ā 
"Protectable subject matters, Protection in biotechnology, Protection of othe...
"Protectable subject matters, Protection in biotechnology, Protection of othe..."Protectable subject matters, Protection in biotechnology, Protection of othe...
"Protectable subject matters, Protection in biotechnology, Protection of othe...
SACHIN R KONDAGURI
Ā 
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
Levi Shapiro
Ā 
Thesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.pptThesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.ppt
EverAndrsGuerraGuerr
Ā 

Recently uploaded (20)

Unit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdfUnit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdf
Ā 
The approach at University of Liverpool.pptx
The approach at University of Liverpool.pptxThe approach at University of Liverpool.pptx
The approach at University of Liverpool.pptx
Ā 
The Roman Empire A Historical Colossus.pdf
The Roman Empire A Historical Colossus.pdfThe Roman Empire A Historical Colossus.pdf
The Roman Empire A Historical Colossus.pdf
Ā 
Overview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with MechanismOverview on Edible Vaccine: Pros & Cons with Mechanism
Overview on Edible Vaccine: Pros & Cons with Mechanism
Ā 
How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...
Ā 
A Strategic Approach: GenAI in Education
A Strategic Approach: GenAI in EducationA Strategic Approach: GenAI in Education
A Strategic Approach: GenAI in Education
Ā 
Instructions for Submissions thorugh G- Classroom.pptx
Instructions for Submissions thorugh G- Classroom.pptxInstructions for Submissions thorugh G- Classroom.pptx
Instructions for Submissions thorugh G- Classroom.pptx
Ā 
Honest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptxHonest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptx
Ā 
Lapbook sobre os Regimes TotalitƔrios.pdf
Lapbook sobre os Regimes TotalitƔrios.pdfLapbook sobre os Regimes TotalitƔrios.pdf
Lapbook sobre os Regimes TotalitƔrios.pdf
Ā 
The Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official PublicationThe Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official Publication
Ā 
Adversarial Attention Modeling for Multi-dimensional Emotion Regression.pdf
Adversarial Attention Modeling for Multi-dimensional Emotion Regression.pdfAdversarial Attention Modeling for Multi-dimensional Emotion Regression.pdf
Adversarial Attention Modeling for Multi-dimensional Emotion Regression.pdf
Ā 
BƀI Tįŗ¬P Bį»” TRį»¢ TIįŗ¾NG ANH GLOBAL SUCCESS Lį»šP 3 - Cįŗ¢ NĂM (CƓ FILE NGHE Vƀ ĐƁP Ɓ...
BƀI Tįŗ¬P Bį»” TRį»¢ TIįŗ¾NG ANH GLOBAL SUCCESS Lį»šP 3 - Cįŗ¢ NĂM (CƓ FILE NGHE Vƀ ĐƁP Ɓ...BƀI Tįŗ¬P Bį»” TRį»¢ TIįŗ¾NG ANH GLOBAL SUCCESS Lį»šP 3 - Cįŗ¢ NĂM (CƓ FILE NGHE Vƀ ĐƁP Ɓ...
BƀI Tįŗ¬P Bį»” TRį»¢ TIįŗ¾NG ANH GLOBAL SUCCESS Lį»šP 3 - Cįŗ¢ NĂM (CƓ FILE NGHE Vƀ ĐƁP Ɓ...
Ā 
CACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdfCACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdf
Ā 
Supporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptxSupporting (UKRI) OA monographs at Salford.pptx
Supporting (UKRI) OA monographs at Salford.pptx
Ā 
2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...
Ā 
Chapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptxChapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptx
Ā 
Palestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptxPalestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptx
Ā 
"Protectable subject matters, Protection in biotechnology, Protection of othe...
"Protectable subject matters, Protection in biotechnology, Protection of othe..."Protectable subject matters, Protection in biotechnology, Protection of othe...
"Protectable subject matters, Protection in biotechnology, Protection of othe...
Ā 
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
Ā 
Thesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.pptThesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.ppt
Ā 

adrenalinenoradrenaline-150926040208-lva1-app6892.pdf

  • 1. Adrenaline & noradrenaline Dr Nida Fatima jawaharlal nehru medical college , AMU ALIGARH
  • 2. adrenaline ā€¢ Catecholamine, sympatho-mimetic monoamine, derived - phenylalanine and tyrosine. ā€¢ C9H13NO3 ā€¢ MOL WT:183.20442 g/mol
  • 5. Types of ļ”-adrenergic receptor Receptor Sites of action Effects ļ”1 smooth muscle, heart, and liver vasoconstriction, intestinal relaxation, uterine contraction and pupillary dilation, ļ”2 platelets, vascular smooth muscle, nerve termini, and pancreatic islets platelet aggregation, vasoconstriction, and inhibition of NE release and of insulin secretion.
  • 6. Types of Ī²-adrenergic receptor Receptor Sites of action Effects Ī²1 Heart tachycardia Ī²2 lungs, gastrointestinal tract, liver, uterus, vascular smooth and skeletal muscle Bronchodilatation Smooth muscle relaxation, sphincter constriction Ī²3 Fat cells
  • 7. Receptors and signal transduction in the ANS Adrenergic Receptors ļ”1A ļ”1 ļ¢ ļ”2 ļ”1B ļ”1D ļ”2A ļ”2B ļ”2C ļ¢1 ļ¢2 ļ¢3
  • 8. Classification of Adrenergic Hormone Receptors Receptor Agonists Second Messenger G protein alpha1 (ļ”1) NE > E IP3/Ca2+; DAG Gq alpha2 (ļ”2) E > NE ļ‚Æ cyclic AMP Gi beta1 (ļ¢1) E = NE ļ‚­ cyclic AMP Gs beta2 (ļ¢2) E >> NE ļ‚­ cyclic AMP Gs E = epinephrine; NE = norepinephrine
  • 11. ADRENALINE PREPARATIONS ā€¢ Clear solution conc. of 1:1000 (1ml amp) or 1:10 000 (10 ml mini-jet for resuscitation). ā€¢ Along with L.A- conc. of 1:200 000, upto 1:80 000 (Lignocaine 2% for dental inj). ā€¢ Auto-injectors for use in anaphylaxis ā€¢ 0.3 mg and 0.15 mg (EpiPenĀ®) for i.m inj.
  • 12. SIDE EFFECTS ā€¢ Exaggerated effects of adrenaline, overdosage, inadvertent i.v injection , inappropriate use. ā€¢ palpitations, tremor, light headedness ā€¢ tachycardia, arrhythmias, hypertension ā€¢ cerebral haemorrhage ,acute pulmonary edema ā€¢ lactic acidosis
  • 13. Effects of adrenaline on organs and tissues in the body ORGAN EFFECT RECEPTOR TYPE Heart Increase heart rate Increased contractility Ī²1 Ī²1 Blood vessels Vasoconstriction Vasodilation Ī±1 Ī²2 Lungs Bronchodilation Ī²2 Uterus Relaxation Ī²2
  • 14. ORGAN EFFECT RECEPTOR Metabolism Inhibits pancreatic insulin secretion Ī±2Ī²2 Glycogenolysis in liver and muscle Ī±1Ī²2 Glycolysis in muscle Ī±1Ī²2 Gluconeogenesis Ī±1Ī²2 Glucagon secretion in pancreas Ī±2 ACTH secretion by pituitary Ī² Lipolysis in adipose tissue Ī²2Ī²3 Renin secretion from kidney Ī²1Ī²2
  • 15. RESUSCITATION ā€¢ Adrenaline - DOC -cardiac arrest. ā€¢ Main action - ā†‘ vascular resistance via Ī±1 vasoconstriction ā†’ improves perfusion pressure to the myocardium and brain. ā€¢ Adrenaline -greatest effect when given i.v intraosseous route if i.v route not patent.
  • 16. ADR IN ACLS ā€¢ VF/VT cardiac arrest -1mg ,in the third cycle after 2 shocks and then every 3-5 minutes (alternate CPR cycles). ā€¢ PEA arrest -1 mg, and then every 3-5 minutes (alternate cycles). ā€¢ Children-10 micrograms ( 0.1 mL of the 1:10,000 solution) per kg i.v ,repeated every 3-5 minutes.
  • 17. ADR IN ACLS ā€¢ Bradycardia: 1mg ADR with 500ml of NS or D5W. Infusion @ 2-10 Āµg/min (titrated to effect). ā€¢ ROSC hypotension: 0.1-0.5 mcg/kg/min ā€¢ Endotracheal Tube: 2-2.5mg ADR is diluted in 10cc NS and given directly into ET tube.
  • 18. ANAPHYLAXIS ā€¢ Adrenaline is the drug of choice. ā€¢ Ī±1-agonist, reverses -peripheral vasodilation by inflammatory mediator release,ā†“ oedema. ā€¢ Ī² activity dilates bronchial airways, ā†‘myocardial contractility, ā†“ histamine and LT release and ā†“ severity of IgE-mediated allergic reactions.
  • 19. Management of acute anaphylaxis AGE IM DOSE (micrograms) (ml of 1:1000 solution) IV DOSE (micrograms) (ml of 1:10 000 solution) Adult 500 micrograms (0.5 ml) 50 micrograms (0.5 ml) titrated to effect Child > 12 years 500 micrograms (0.5 ml) 50 micrograms (0.5 ml) titrated to effect Child 6-12 years 300 micrograms (0.3 ml) 1 microgram/kg titrated to effect Child < 6 years 150 micrograms (0.15 ml) 1 microgram/kg titrated to effect
  • 20. ANAPHYLAXIS DOSES ā€¢ Adults-initial dose is 100 to 500 microgram (0.1 to 0.5 mL of the 1:1,000 sol) SC or IM. ā€¢ repeated at 20 minute to 4 hour intervals ā€¢ severe anaphylactic shock, slow and cautious IV administration-100 to 250 microgram ā€¢ Children-10 microgram per kg SC repeated at intervals of 20 min to 4 hrs
  • 21. INOTROPIC SUPPORT ā€¢ Continuous infusion in ICU- via CVP line, with invasive blood pressure monitoring. ā€¢ Indications : ā€¢ profoundly low blood pressure, ā€¢ shock, ā€¢ low cardiac output states and ā€¢ status asthmaticus.
  • 22. ā€¢ There is no single appropriate concentration. ā€¢ 4 mg Adrenaline diluted to 50 ml in saline or 5% dextrose, infused by means of a syringe driver. ā€¢ Rate of infusion -titrated to effect, to achieve target blood pressure.
  • 23. AIRWAY OBSTRUCTION ā€¢ Severe croup-m/c airway indication for Adr. ā€¢ angio-oedema- life threatening obstruction. ā€¢ racemic adrenaline -nebulized route. ā€¢ MOA-reduce the local inflammatory process and to provide local vasoconstriction- reducing obstruction caused by oedema.
  • 24. DOSAGE ā€¢ L-Adrenaline-0.5 ml/kg of a 1:1000 solution (maximum of 5 ml) placed undiluted into the chamber of the nebulizer for children. ā€¢ Racemic -0.05 ml/kg (max 1.5 ml) of 2.25% sol diluted to 4 ml NS.
  • 25. Topical or local vasoconstriction ā€¢ Local vasoconstricting action- adrenaline used as a topical application or combined with local anaesthetic to be infiltrated. ā€¢ Prolongs its action, reduces bleeding at the site of injection or topically (nasal mucosa as part of Moffatā€™s solution)
  • 26. CONTRA-INDICATIONS ā€¢ Known hypersensitivity ā€¢ Shock (other than anaphylactic shock) ā€¢ Cardiac dilatation and insufficiency ā€¢ Hypertension ā€¢ Ischaemic heart disease ā€¢ Arrhythmias ā€¢ Cerebral arteriosclerosis
  • 27. ā€¢ Diabetes mellitusĀ· ā€¢ Hyperthyroidism ā€¢ Narrow angle (congestive) glaucoma ā€¢ Organic brain damage ā€¢ Phaeochromocytoma / thyrotoxicosis ā€¢ halogenated hydrocarbons or cyclopropane ā€¢ L.A in fingers, toes, ears, nose or genitalia ā€¢ Labour
  • 28. NORADRENALINE Mol formula C8H11NO3 Catecholamine with multiple roles: ā€¢Hormone ā€¢Neurotransmitter.
  • 30. ACTIONS ā€¢ Stress hormone ā€¢ Fight-or-flight response ā€¢ Increases heart rate ā€¢ Triggers the release of glucose ā€¢ Increases blood flow to skeletal muscle. ā€¢ Suppress neuro-inflammation.
  • 31. Noradrenergic system ā€¢ Amygdala ā€¢ Cingulate gyrus ā€¢ Cingulum ā€¢ Hippocampus ā€¢ Hypothalamus ā€¢Neocortex ā€¢ Spinal cord ā€¢ Striatum ā€¢ Thalamus
  • 32. VESICULAR TRANSPORT ā€¢ Between the decarboxylation and final Ī²- oxidation, norepinephrine is transported into synaptic vesicles. ā€¢ Accomplished by vesicular monoamine transporter (VMAT) in the lipid bilayer. ā€¢ This transporter has equal affinity for norepinephrine, epinephrine and isoprenaline
  • 33. PHARMACODYNAMICS ā€¢ Potent action-both a1 & b1 receptors ā€“Little action on b2 ā€“Causes potent vasoconstriction (Ī±) ā€“Lacks bronchodilating effect ā€“ā†‘ systolic, diastolic & MAP ā€“Reflex bradycardia ā€“Metabolic acidosis
  • 34. PHARMACOKINETICS Onset- 1-2 min Duration- 1-2 min Metabolism- by COMT and MAO Distribution ā€¢ Sympathetic nervous tissue. ā€¢ Crosses the placenta not blood-brain barrier. Excretion- mainly urine (84-96%)
  • 35. HYPOTENSIVE STATES ā€¢ First-line therapy for maintenance of B.P and tissue perfusion in septic shock. ā€¢ adjunct to correct hemodynamic imbalances ā€¢ Start:8-12 Āµg/min IV infusion; titrate to effect ā€¢ Maintenance: 2-4 mcg/min IV infusion ā€¢ Septic shock: 0.01-3 mcg/kg/min IV infusion
  • 36. Cardiac Arrest ā€¢ Adjunctive Treatment in Cardiac Arrest ā€¢ Infusions of noradrenaline given during cardiac arrest to restore and maintain an adequate blood pressure after an effective heartbeat and ventilation have been established by other means. ā€¢ Initial: 8-12 mcg/min IV infusion; titrate to effect ā€¢ Maintenance: 2-4 mcg/min IV infusion
  • 37. DOSAGE ā€¢ The usual dose range is 0.01-0.1 m/kg/min ā€¢ Avg. adult maintenance dosage: 2ā€“4 Āµg/min ā€¢ May require 8ā€“30 mcg/minute in cases of refractory shock ā€¢ Drug is diluted with 5% dextrose or dextrose normal saline
  • 38. ā€¢ administered through central venous line to minimize the risk of extravasation and subsequent tissue necrosis ā€¢ control rate and strict monitoring ā€¢ must not be stopped suddenly, gradually withdrawn to avoid disastrous falls in blood pressure Noradrenaline infusion
  • 39. Noradrenaline infusion ā€¢ 4mg = 4mL of 1:1000 ā€¢ Add 4mL of 1:1000 Noradrenaline to 46mL 5% Glucose to make 50mL ā€¢ Starting dose- 0.025microgram/kg/minute ā€¢ the rate in mL/hour
  • 41. ADVERSE EFFECTS ļ‚§ Hypertension , bradycardia, arrhythmias, palpitations ļ‚§ Ischemic injury -potent vasoconstriction. ļ‚§ Anxiety, insomnia, confusion, ļ‚§ Headaches, psychosis ļ‚§ Weakness, tremor ļ‚§ Anorexia, nausea and vomiting.
  • 42. Extravasation ā€¢ Infusion site-checked frequently for free flow. ā€¢ Avoid extravasation of noradrenaline ā€¢ Local necrosis -vasoconstrictive action ā€¢ Blanching- change infusion site ā€¢ Extravasation-infiltrate area ā†’ 10 ml-15 ml of saline solution containing 5 mg to 10 mg of phentolamine.
  • 43. Comparison Features Adrenaline Noradrenaline Heart rate ā†‘ ā†“ Cardiac output ā†‘ā†‘ -- Blood pressure-systolic ā†‘ā†‘ ā†‘ā†‘ diastolic ā†‘ā†“ ā†‘ā†‘ mean ā†‘ ā†‘ā†‘ Bronchial muscle ā†“ā†“ -- Intestinal muscle ā†“ā†“ ā†“ Blood sugar ā†‘ā†‘ --, ā†‘
  • 44. Drug interaction ā€¢ Non-selective MAO inhibitors ā€¢ selective MAO inhibitors ā€¢ Linezolid ā€¢ Thyroid hormones ā€¢ Cardiac glycosides ā€¢ Ergot alkaloids or oxytocin # enhance the vasopressor and vasoconstrictive effects.
  • 45. CONTRA-INDICATIONS ā€¢ Known hypersensitivity ā€¢ hypotensive from blood volume deficits ā€¢ mesenteric or peripheral vascular thrombosis ā€¢ Cyclopropane and halothane anesthetics